Company: PCRX
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001396814-25-000061
Chunk: 157

Company: Pacira BioSciences, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 8
Chunk 157
---
 Form 10-Q  |  Page 27

Potential common shares are excluded from the diluted net income per common share computation to the extent they would be antidilutive. The following table sets forth the computation of basic and diluted net income per common share for the three months ended March 31, 2025 and 2024 (in thousands, except per common share amounts):Three Months EndedMarch 31,20252024Numerator:   Net income—basic$4,812 $8,979 2025 Notes if-converted method adjustment— 1,029    Adjusted net income—diluted$4,812 $10,008 Denominator:   Weighted average common shares outstanding—basic46,275 46,499 Computation of diluted securities:2025 Notes if-converted method adjustment— 5,608    Dilutive effect of stock options20 1    Dilutive effect of RSUs227 85 Dilutive effect of ESPP share options4 —    Weighted average common shares outstanding—diluted46,526 52,193 Net income per common share:   Basic and diluted net income per common share$0.10 $0.19 The following table summarizes the outstanding stock options, RSUs, ESPP share options and convertible senior notes that were excluded from the diluted net income per common share calculation because the effects of including these potential shares were antidilutive in the periods presented (in thousands):Three Months EndedMarch 31,20252024Weighted average number of stock options6,677 7,662 2025 Notes if-converted method adjustment2,821 — Weighted average number of RSUs2,363 1,230 Weighted average ESPP share options— 52       Total11,861 8,944 

NOTE 14—INCOME TAXES

Income (loss) before income taxes and income tax expense are as follows (dollar amounts in thousands):Three Months EndedMarch 31,20252024Income (loss) before income taxes:   Domestic$10,673 $13,657    Foreign(1,967)(17)Total income before income taxes$8,706 $13,640 Income tax expense$3,894 $4,661 Effective tax rate45 %34 %

Pacira BioSciences, Inc.  |  Q1